



Research Article

Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients

Shuhang Wang¹, Huiyao Huang¹, Minghui Zhang², Zicheng Yu³, Fend Xie⁴, Shidong Jia⁴, Yixuan Ren⁵, Danyi Wen⁵, Ning Li^{6*}

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cell Biology, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China

²Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China

³GenePlus-Shenzhen, Shenzhen, China

⁴Huidu Shanghai Medical Sciences, Shanghai, China

⁵Shanghai LIDE Biotech, Shanghai, China

⁶Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

***Corresponding Author:** Ning Li, Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China, Tel: 010-67781331

Received: 07 April 2020; **Accepted:** 03 May 2021; **Published:** 21 May 2021

Citation: Shuhang Wang, Huiyao Huang, Minghui Zhang, Zicheng Yu, Fend Xie, Shidong Jia, Yixuan Ren, Danyi Wen, Ning Li. Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients. *Journal of Cancer Science and Clinical Therapeutics* 5 (2021): 235-249.

https://fortunejournals.com/supply/JCSCT_3499.xlsx

Supplementary Table 1

Specimen Types	EGFR Status	Pleural Effusion Supernatant					Pleural Effusion Cells				
		Mutated	Wild-type	P-value	Sensitivity	Specificity	Mutated	Wild-type	P-value	Sensitivity	Specificity
Plasma	Mutated	4	0	1	1	0.8	4	0	0.2	1	1
	Wild-type	1	0				0	1			
Pleural Effusion Supernatant	Mutated	\	\	\	\	\	4	1	1	\	\
	Wild-type	\	\	\	\	\	0	0		\	\
BCR Status											
Plasma	Mutated	1	0	1	1	0.33	1	0	0.4	1	0.5
	Wild-type	2	2				1	3			
Pleural Effusion Supernatant	Mutated	\	\	\	\	\	2	0	0.4	\	\
	Wild-type	\	\	\	\	\	1	2		\	\
SUFU Status											
Plasma	Mutated	2	0	0.1	1	1	2	0	0.1	1	1
	Wild-type	0	3				0	3			
Pleural Effusion Supernatant	Mutated	\	\	\	\	\	2	0	0.1	\	\
	Wild-type	\	\	\	\	\	0	3		\	\
DNMT3A Status											
Plasma	Mutated	2	0	0.1	1	1	2	0	0.1	1	1

	Wild-type	0	3				0	3			
Pleural Effusion	Mutated	\	\	\	\	\	2	0	0.1	\	\
Supernatant	Wild-type	\	\	\	\	\	0	3		\	\
TP53 Status											
Plasma	Mutated	1	0	0.4	1	0.5	1	0	0.4	1	0.5
	Wild-type	1	3				1	3			
Pleural Effusion	Mutated	\	\	\	\	\	1	0	0.2	\	\
Supernatant	Wild-type	\	\	\	\	\	0	4		\	\
CTNNB1 Status											
Plasma	Mutated	1	0	0.2	1	1	1	0	0.2	1	1
	Wild-type	0	4				0	4			
Pleural Effusion	Mutated	\	\	\	\	\	1	0	0.2	\	\
Supernatant	Wild-type	\	\	\	\	\	0	4		\	\
FAT1 Status											
Plasma	Mutated	1	0	0.2	1	1	1	0	0.2	1	1
	Wild-type	0	4				0	4			
Pleural Effusion	Mutated	\	\	\	\	\	1	0	0.2	\	\
Supernatant	Wild-type	\	\	\	\	\	0	4		\	\

Supplementary Table 2

Patient ID	Gender	Age at Diagnosis	Pathological Type	Stage of Disease (TNM)	Metastatic Site	Administered TKI	Time of PD to TKI Administered (Month)	Time of Sampling to PD (Month)
P1	Male	54	Adenocarcinoma	IV	Brain	Osimertinib	16.0	1.6
P2	Female	60	Adenocarcinoma	IV	Bone, Brain	Osimertinib	6.5	0.4
P3	Female	68	Adenocarcinoma	IV	Bone, Adrenal Gland	Osimertinib	3.2	0.4
P4	Female	68	Squamous Cell Carcinoma	III-B	/	Osimertinib	32.0	4.4
P5	Female	53	Adenocarcinoma	IV	Bone, Liver	Osimertinib	19.0	8.8
P6	Male	41	Adenocarcinoma	IV	Liver	Osimertinib	3.0	0.3
P7	Female	64	Adenocarcinoma	III-B	/	Osimertinib	17.0	0.9
P8	Female	49	Adenocarcinoma	IV	Bone	Osimertinib	9.0	1.0

Supplementary Table 3



This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC-BY\) license 4.0](https://creativecommons.org/licenses/by/4.0/)